Photo from Day One Biopharmaceuticals/LinkedIn
Jul 29, 2024, 07:51
Day One Biopharmaceuticals’ new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib
Day One Biopharmaceuticals shared a post on LinkedIn:
“We are pleased to announce a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib. This collaboration highlights our shared commitment to bring novel therapeutics to patients worldwide who have limited treatment options. Learn more.”
shared the post by Day One Biopharmaceuticals on LinkedIn, adding:
“Excited to partner with Ipsen to help kids and families with pediatric low grade gliomas worldwide!”
Source: Day One Biopharmaceuticals/LinkedIn and
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 27, 2025, 07:28
Apr 27, 2025, 07:18
Apr 27, 2025, 05:33
Apr 27, 2025, 05:14
Apr 27, 2025, 03:52